ABSTRACT We found in two previous studies (Down syndrome patients and end-stage kidney patients receiving renal dialysis) that total serum iron is higher on average in carriers of the hepatitis B virus than in those who are not. The elevation of the serum iron is independent of elevations of serum L-alanine:2-oxoglutarate aminotransferase, EC 2.6.1.2) (SGPT), an indicator of liver cell damage. We have followed for 10 yr a large number of patients with end-stage renal disease receiving renal dialysis. In this paper we describe studies of serum iron and SGPT levels in patients (i) 1 mo before infection, (ii) after infection but within the month of infection, and (iii) 6-12 mo after infection. Comparisons of serum iron levels were made between those infected who retained the virus (carriers) and those who rejected the infection (transients). There were no differences between these groups before infection. Serum iron remained high in the carrier group and dropped in the transients. However, not all of the carriers retained high levels, although this was the case in general. Individual changes in the pre-and postconversion period were then considered. All carriers who had a preconversion decline in iron had an increase after infection, whereas this occurred in only some of the transients. Those carriers who had a decline after infection had raised levels before infection, and the decline was generally less than the increase. Consideration of the SGPT and the iron levels together led to the same conclusion as the previous studies, that elevation of iron may be independent of rise in SGPT. Several hypotheses were derived from these findings. Individuals who are carriers in general have higher iron levels and, therefore, are more likely to become infected with bacteria; this may contribute to increased morbidity and mortality. From experimental evidence, iron is required for the growth of tumor cells. Carriers with elevated iron levels may be more likely to develop detectable cancer of the liver than those who do not.
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Serum iron appears to play an important role in the body's defense against many bacterial infections (1). The response of the body after infection is to decrease iron absorption through the intestine, which is normally the major source ofbody iron. This has the effect of decreasing the iron available to the infecting organism and, thereby, decreasing its probability of survival. Iron is also required for the growth of all living cells, including tumor cells. Fernandez-Pol (2) has shown that a plant substance, picolinic acid, inhibits the growth oftumor cells in tissue culture as a consequence ofthe chelation of iron (but not zinc), thereby depriving the cells ofa necessary growth substance. Serum iron is known to be elevated in hepatitis, presumably as a result of the disruption ofliver cells and the addition oftheir iron content to that of the serum.
Until recently there was not much information on iron levels in carriers of hepatitis B virus (HBV). We became interested in understanding more about this phenomenon because of the accumulating evidence to support the hypothesis that persistent infection with HBV is required for the development of most cases of primary hepatocellular carcinoma (PHC) (3) .
Previously, we studied two groups of patients with high frequencies of HBV carriers. In male Down syndrome patients, we found carriers to have significantly higher levels of serum iron and higher levels of percent serum iron saturation than patients who were not carriers (4) . The iron levels were not correlated with serum glutamic-pyruvic transaminase (SGPT; serum L-alanine:2-oxoglutarate aminotransferase, EC 2.6.1.2) levels (a liver enzyme whose presence indicates liver damage). A similar study was done in patients with end-stage renal disease treated at a renal dialysis unit in Philadelphia, PA (5) . Again, the serum iron levels and percentage iron bound were higher in the carriers than noncarriers. There was a correlation with SGPT and also an independent correlation with the presence of HBV. Both of these studies are consistent with the explanation that the increase in iron was not only the result of liver cell breakdown but of the presence of the HBV itself.
These that, in this clinic, the probability of remaining HBsAg(+) indefinitely after being positive for at least 6 mo exceeds 90% (6) .
There were 34 transients and 33 carriers. Three samples over time were tested from each of these patients: (i) 1 mo before seroconversion to HBsAg(+); (ii) first drawing after seroconversion to HBsAg(+); and (iii) 6-12 mo after seroconversion.
Assays. Iron These pre-and postseroconversion iron level changes were considered in combination (Table 2, combination). All 12 carriers who had a preseroconversion decline in iron had an increase in iron after seroconversion, whereas 7 of 14 transients declined in both time periods (P < 0.01, one-tailed test). Similarly, all 12 carriers who had a decline in iron after infection had an increase before infection, whereas only 15 of 22 transients had the same pattern (P = 0.03, one-tailed test). That is, there were no carriers who had declining iron in both time periods. From the data on individuals, this represents the only consistent observation that can be made with the iron data alone.
By using SGPT, however, additional insight into the interaction between liver cell breakdown, iron levels, and HBV is possible. In Table 3 , the postseroconversion (sample 2 to sample 3) SGPT For carriers, the mean iron levels before seroconversion were significantly less than the other two values (P < 0.05). Preseroconversion refers to the change between the first and second samples; postseroconversion refers to the change between the second and third samples.
SGPT. The residual x2 is only 0.60 for this model. SGPT and iron do not interact in this model, which is consistent with previous observations that the association of increasing serum iron with the carrier state does not directly depend on liver cell breakdown. This analysis, which is based on patterns of change over time, reaches the same conclusions as the previous work, which was based on the magnitudes ofthe serum iron and SGPT levels at one point in time.
DISCUSSION
There are several biological hypotheses which arise from these findings: (i) The increase in serum iron in carriers could contribute to increased hemoglobin metabolism. This hypothesis can be tested by studies of iron and erythrocyte metabolism in relation to HBV response. Such a study ought to include a number of other factors, such as ferritin, because both the carrier and transient populations appear to be heterogeneous in their changes in serum iron levels.
(ii) A variety of studies recently reviewed have shown that increased iron levels and particularly increased percentage of iron saturation increase the probability of infection with a variety of bacteria. This generates the hypothesis that carriers of the hepatitis virus are more likely to have bacterial infections and that such infections would be more severe than in transiently infected persons. Our laboratory has been studying the effects of HBV infection on fertility and mortality. In general, carriers have decreased fertility and increased mortality. If this hypothesis concerning the bacteria is true, it would provide a partial explanation of the demographic and epidemiologic observations that we have made.
(iii) We recently have summarized the data that provides strong support for the hypothesis that persistent infection with HBV is necessary for the development of PHC. According to this model, nearly all patients with PHC have been persistently infected with HBV, but only a fraction of the carriers will proceed through chronic liver disease on the unfortunate path to PHC (3) . Are the serum iron levels and iron metabolism related to this? In studies of PHC tumor tissues, it has been found that the cancer cells have much less stainable iron storage than nonmalignant cells (9) . By using fluorescent and other indicators for HBsAg and the HBV core antigen, it has been shown that the virus is present in the liver cells of patients with PHC; but the transformed cells usually lack or have small amounts of virus. Fernandez-Pol has found that removal ofiron decreases the growth of experimental liver tumors in tissue cultures. Therefore, the survival of transformed liver cells may depend upon surrounding cells providing the iron needed for growth. Hence, we conjecture that carriers with increased iron levels and levels of factors related to iron would be at greater risk of developing clinically evident liver cancer than carriers with "normal" iron levels and metabolisms.
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